Pfizer turns to late-stage pipeline to make up for Lipitor crash

As expected, Lipitor sales are being blasted by generic competition in the U.S. And with Pfizer's ($PFE) sales numbers plunging, the pharma giant is staying focused on the fate of a trio of late-stage…
Read the full story: News